Who are Kura Oncology, Inc.'s main suppliers?

Kura Oncology, Inc. (KURA) key suppliers include: BMS, MIRATI, KYOWA-KIRIN, Allarity Therapeutics, Inc., Actinium Pharmaceuticals, Inc.. View the full supplier network at chainsifter.com/chain/KURA.

Who are Kura Oncology, Inc.'s major customers?

Kura Oncology, Inc. (KURA) key customers include: KYOWA-KIRIN-INC, KYOWA-KIRIN-CO-LTD, Allarity Therapeutics, Inc., Hercules Capital, Inc., Hercules Capital, Inc. and 7 more. View the full customer network at chainsifter.com/chain/KURA.

What sector is Kura Oncology, Inc. in?

Kura Oncology, Inc. (KURA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Kura Oncology, Inc. Supplier List (KURA): 5 Verified Suppliers

5Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Kura Oncology, Inc. (KURA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

21Total relationships

2Distinct source URLs

9High confidence

0.758Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Kura Oncology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
BMS	BMS	90%	Under the terms of the agreement, Mirati (now a BMS company) supplies us with adagrasib for the NSCLC, CRC and PDAC combin
MIRATI	MIRATI	90%	Under the terms of the agreement, Mirati (now a BMS company) supplies us with adagrasib for the NSCLC, CRC and PDAC combin
KYOWA-KIRIN	KYOWA-KIRIN	80%	Our collaboration with Kyowa Kirin is important to our business.
ALLR	Allarity Therapeutics, Inc.	72%	Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the…
ATNM	Actinium Pharmaceuticals, Inc.	72%	Reciprocal relationship from ATNM graph: Reciprocal relationship from KURA graph: Reciprocal relationship from ATNM graph: eferred to and treated in comprehensive treatment centers for in-patient tre…

Kura Oncology, Inc. Customers

Ticker	Name	Confidence	Evidence
KYOWA-KIRIN-INC	KYOWA-KIRIN-INC	92%	We record all U.S. sales of KOMZIFTI, and we and Kyowa Kirin share equally the profits and losses from the commercialization activities in the United States.
KYOWA-KIRIN-CO-LTD	KYOWA-KIRIN-CO-LTD	85%	cial to patients who are often elderly and on several concomitant medications. We initiated commercial sales of KOMZIFTI in the United States on November 21, 2025. Under the terms of the collaboratio…
ALLR	Allarity Therapeutics, Inc.	72%	Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the…
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from KURA graph: cial to patients who are often elderly and on several concomitant medications. We initiated commercial sales of KOMZI…
HTGC	Hercules Capital, Inc.	72%	cial to patients who are often elderly and on several concomitant medications. We initiated commercial sales of KOMZIFTI in the United States on November 21, 2025. Under the terms of the collaboratio…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	Loans is the greater of (i) the prime rate as reported in The Wall Street Journal minus 6.25% plus 8.65% and (ii) 8.65%. As of March 31, 2026, the interest rate on the Term Loans was 9.15%. In Novemb…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	ur cash in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. 68 FINRA sales practice requirements may limit a stock…
INDEX-TO-EXHIBITS-EXHIBIT-NUMBER-DESCRIPTION-FIL	INDEX-TO-EXHIBITS-EXHIBIT-NUMBER-DESCRIPTION-FIL	62%	in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. We are exposed to the risk that our employees, independent contractors, principal inves…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	cial to patients who are often elderly and on several concomitant medications. We initiated commercial sales of KOMZIFTI in the United States on November 21, 2025. Under the terms of the collaboratio…
MIRATI-THERAPEUTICS-INC	MIRATI-THERAPEUTICS-INC	62%	cial to patients who are often elderly and on several concomitant medications. We initiated commercial sales of KOMZIFTI in the United States on November 21, 2025. Under the terms of the collaboratio…
MITT	TPG Mortgage Investment Trust, Inc.	62%	Reciprocal relationship from MITT graph: Reciprocal relationship from KURA graph: Reciprocal relationship from MITT graph: Reciprocal relationship from KURA graph: Reciprocal relationship from MITT g…
OXFORD-FINANCE-LLC	OXFORD-FINANCE-LLC	62%	in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. We are exposed to the risk that our employees, independent contractors, principal inves…

Kura Oncology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
KURA-DEBT	Debt stack $9.8M	90%	Market cache reports total debt of $9.8M.
KURA-DEBT-10585	Warrants outstanding: 294000	90%	xbrl warrant detail from xbrl 2022-12-31.
KURA-DEBT-10586	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2015-12-31.

Kura Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kura Oncology, Inc..

Kura Oncology, Inc. Ownership

Holder	Name	Confidence	Evidence
KURA-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 218 tracked holders.

Kura Oncology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MAZE	Maze Therapeutics, Inc.	100.00	2
VRDN	Viridian Therapeutics, Inc.	100.00	2
MITT	TPG Mortgage Investment Trust, Inc.	100.00	1	['customer']
REPL	Replimune Group, Inc.	100.00	2
ATNM	Actinium Pharmaceuticals, Inc.	100.00	1	['supplier']
OBIO	Orchestra BioMed Holdings, Inc.	100.00	2
MDGL	Madrigal Pharmaceuticals, Inc.	100.00	2
ALT	Altimmune, Inc.	100.00	2
SGHT	Sight Sciences, Inc.	100.00	2
RCUS	Arcus Biosciences, Inc.	100.00	2
ALLR	Allarity Therapeutics, Inc.	100.00	1	['customer', 'supplier']
ALEC	Alector, Inc.	100.00	2
CMPS	COMPASS Pathways plc	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
IRON	Disc Medicine, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
ENGN	enGene Therapeutics Inc.	100.00	2
SVRA	Savara Inc.	100.00	2
PHGE	BiomX Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	50.00	2

Kura Oncology, Inc. Supply Chain